Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-B01D1 + TKI ± pembrolizumab in advanced renal cancer
NCT06962787Phase 2Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Jul 2025
- Primary completion
- May 2027
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of izalontamab brengitecan in renal cell carcinoma (RCC), sponsored by Biokin Pharmaceutical. Started Jul 2025; status: recruiting.
02
Drugs
izalontamab brengitecan
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT06962787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06962787.